



**NOTIFICATION**

*Addendum*

The following communication, dated , is being circulated at the request of the delegation of Brazil.

**Title:** Resolution – RDC number 624, 09 March 2022

<b>Reason for Addendum:</b>	
<input type="checkbox"/>	Comment period changed - date:
<input type="checkbox"/>	Notified measure adopted - date:
<input type="checkbox"/>	Notified measure published - date:
<input type="checkbox"/>	Notified measure enters into force - date:
<input type="checkbox"/>	Text of final measure available from <sup>1</sup> :
<input checked="" type="checkbox"/>	Notified measure withdrawn or revoked - date: 21 March 2023 Relevant symbol if measure re-notified:
<input type="checkbox"/>	Content or scope of notified measure changed and text available from <sup>1</sup> : New deadline for comments (if applicable):
<input type="checkbox"/>	Interpretive guidance issued and text available from <sup>1</sup> :
<input type="checkbox"/>	Other:

**Description:** The Resolution – RDC number 624, 09 March 2022 - previously notified through G/TBT/N/BRA/1322 - which contains provisions on the control by Brazilian Health Regulatory Agency (Anvisa) of the importation of raw materials, manufacture, distribution, commercialization, medical prescription and application of ganglioside - based drugs, was revoked by Resolution - RDC number 782, 17 May 2023.

The final text is available only in Portuguese and can be downloaded at:

[http://antigo.anvisa.gov.br/documents/10181/6532116/RDC\\_782\\_2023\\_.pdf/f565604a-2db6-4f69-9a1a-5629f6d29025](http://antigo.anvisa.gov.br/documents/10181/6532116/RDC_782_2023_.pdf/f565604a-2db6-4f69-9a1a-5629f6d29025)

<sup>1</sup> This information can be provided by including a website address, a pdf attachment, or other information on where the text of the final/modified measure and/or interpretive guidance can be obtained.